Details for Patent: 4,585,790
✉ Email this page to a colleague
Summary for Patent: 4,585,790
Title: | Pharmaceutical compositions |
Abstract: | Aqueous formulations of raniditine have been found to have enhanced shelf life provided that they are formulated with a pH in the range 6.5--7.5. Suitable aqueous formulations include injections for intravenous and intramuscular administration, continuous infusions and oral preparations such as syrups. |
Inventor(s): | Padfield; John M. (Meldreth, GB2), Winterborn; Ian K. (Stevenage, GB2) |
Assignee: | Glaxo Group Limited (London, GB2) |
Application Number: | 06/609,215 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; Process; |
Drugs Protected by US Patent 4,585,790
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 4,585,790
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
United Kingdom | 83 13217 | May 13, 1983 |
International Family Members for US Patent 4,585,790
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2792984 | ⤷ Sign Up | |||
Australia | 568647 | ⤷ Sign Up | |||
Belgium | 899635 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |